期刊文献+

集束化治疗预防呼吸机相关性肺炎研究 被引量:5

Study of bundle therapy in preventing ventilator associated pneumonia
在线阅读 下载PDF
导出
摘要 目的研究集束化治疗预防呼吸机相关性肺炎(VAP)的有效性。方法选取机械通气>48小时的患者,2014年6月至2015年5月为对照组,2015年6月至2016年5月为集束化治疗组。观察两组患者的VAP的发生率,机械通气时间,ICU住院时间及迟发性VAP发生率。结果 VAP发生率对照组为47.22%,集束化治疗组为23.81%,两者之间有统计学差异(P=0.035);机械通气时间,对照组为11.03±4.87天,集束化治疗组为9.02±3.75天,两者之间有统计学差异(P=0.044);ICU住院时间对照组为15.17±5.96天,集束化治疗组为12.81±4.59,两者之间无统计学差异(P=0.052);迟发性VAP对照组为82.35%,集束化治疗组为50%,两者之间无统计学差异(P=0.102)。结论集束化治疗可有效预防VAP的发生。 Objective To study the effectiveness of bundle therapy in preventing ventilator associated pneumonia. Methods Patients with mechanical ventilation more than 48 hours were included in our study and divided into two groups. The patients from June 2014 to May 2015 was the control group,and from June 2015 to May 2016 was the therapy group. The incidence of VAP,MV duration,ICU stay and late-onset VAP of the two groups were studied. Results The incidence of VAP was 47. 22% in the control group and 23. 81% in the therapy group( P =0. 035). MV duration was 11. 03 ± 4. 87 days in the control group and 9. 02 ± 3. 75 days in the bundle therapy group( P = 0. 044). ICU stay was 15. 17 ± 5. 96 days in the control group and 12. 81 ± 4. 59 days in the bundle therapy group( P = 0. 052). Late-onset VAP was 82. 35% in the control group and 50% in the bundle therapy group( P =0. 102). Conclusion Bundle therapy can prevent ventilator associated pneumonia effectively.
作者 李晓东 孙艳辉 郝伟佳 张翠苹 杨鹏 LI Xiao-dong;SUN Yan-hui;HAO Wei-jia;ZHANG Cui-ping;YANG Peng(Beijing Mentougou District Hospital,Beijing 102300,China)
出处 《临床肺科杂志》 2018年第1期60-62,共3页 Journal of Clinical Pulmonary Medicine
关键词 呼吸机相关性肺炎 集束化治疗 机械通气 ventilator associated pneumonia bundle therapy mechanical ventilation
  • 相关文献

参考文献2

二级参考文献24

  • 1[1]Bauer TT, Ferrer R, Angrill J, et al. Ventilator-associated pneumonia: incidence, risk factors, and microbiology[J]. Semin Respir Infect, 2000, 15(4): 272-279.
  • 2[2]Cook D. Ventilator associated pneumonia: perspectives on the burden of illness[J]. Intensive Care Med, 2000, 26 Suppl 1: S31-S37.
  • 3[3]Morehead RS, Pinto SJ. Ventilator-associated pneumonia[J]. Arch Intern Med, 2000, 160(13): 1926-1936.
  • 4[4]Kollef MH. Epidemiology and risk factors for nosocomial pneumonia[J]. Clin Chest Med, 1999, 20: 653-670.
  • 5[5]Mathews PJ, Mathews LM. Reducing the risks of ventilator-associated infections[J]. Dimens Crit Care Nurs, 2000, 19: 17-21.
  • 6[7]Daren KH, John WD, Shaun MD, et al. Effect of postpyloric feeding on gastroesophageal regurgitation and pulmonary microaspiration: results of a randomized controlled trial[J]. Crit Care Med, 2001, 29(8): 1495-1501.
  • 7[9]Finkelstein R, Rabino G, Kassis I, et al. Device-associated,device-day infection rates in an Israeli adult general intensive care unit[J]. J Hosp Infect, 2000, 44: 200-205.
  • 8[11]Torres A, Fàbregas N, Ewig S, et al. Sampling methods for ventilator-associated pneumonia: validation using different histologic and microbiological references[J]. Crit Care Med, 2000, 28(8): 2799-2804.
  • 9[12]Marik PE, Varon J. Ventilator-associated pneumonia : science and hocus-pocus[J]. Chest, 2001, 120(3): 702-704.
  • 10[13]Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit[J]. Ann Intern Med, 2001, 134: 298-314.

共引文献287

同被引文献61

引证文献5

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部